More drama ahead: Sarepta plans to file for accelerated Duchenne approval, with adcomm a 'near certainty'
While Sarepta has three antisense oligonucleotide therapies approved — albeit not without controversy — for Duchenne muscular dystrophy, it has been working on a long-term treatment in the form of a gene therapy.
After posting positive results for its Roche-partnered gene therapy, dubbed SRP-9001, earlier this month, the Cambridge, MA-based biotech says it now intends to pursue an accelerated approval for its latest Duchenne treatment. Sarepta shares $SRPT rose about 10% on the news in early Friday trading.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.